-
Mashup Score: 0Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma - Leukemia - 3 year(s) ago
Leukemia –
Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory… Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9 - Leukemia - 3 year(s) ago
To investigate clonal hematopoiesis associated gene mutations in vitro and to unravel the direct impact on the human stem and progenitor cell (HSPC) compartment, we targeted healthy, young hematopoietic progenitor cells, derived from umbilical cord blood samples, with CRISPR/Cas9 technology. Site-specific mutations were introduced in defined regions of DNMT3A, TET2, and ASXL1 in CD34+ progenitor…
Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9 Read for free: https://t.co/VjzcwWQ1fi #Cancergenetics #Myelodysplasticsyndrome https://t.co/pdEyOoHTxf
-
-
Mashup Score: 5Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration - Leukemia - 3 year(s) ago
In AML patients, recurrent mutations were shown to persist in remission, however, only some have a prognostic value and persistent mutations might therefore reflect a re-established premalignant state or truly active disease causing relapse. We aimed to dissect the nature of co-mutations in NPM1 mutated AML where the detection of NPM1 transcripts allows highly specific and sensitive detection of…
Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration [Aug 10, 2021] Luca Vincenzo Cappelli et al. @LeukemiaJnl https://t.co/bffwCpB7H2 #AML #leusm #mdssm #camoldx #OpenAccess https://t.co/PbfCrb7iAQ
-
-
Mashup Score: 1
Leukemia –
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of… Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
đ KEY POINTS âȘïž The GMMG-CONCEPT phase II trial is investigating isatuximab, carfilzomib, lenalidomide, & dexamethasone in front-line treatment of high-risk multiple #myeloma âȘïž interim analysis show encouraging rates of rapid and deep remissions https://t.co/VdxTSzIlAo #mmsm
-
-
Mashup Score: 2
The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the best treatment option remains controversial especially when choosing between intensive chemotherapy and hypomethylating agents. We set up a multicentric European database collecting data of 3 700 newly diagnosed acute myeloid leukemia patients â„70 years. The primary objective was to compare overall…
Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries Read for free: https://t.co/H39OnMMcLM https://t.co/K7bWISL96g
-
-
Mashup Score: 2Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis - Leukemia - 3 year(s) ago
The association between familial plasma cell disorders (PCD) and prognosis in patients with MGUS, multiple myeloma (MM), and systemic light chain (AL) amyloidosis has not been well described. This study retrospectively reviewed outcomes of 25,423 patients (16,744 MGUS, 6194 MM, 2955 AL amyloidosis). Overall, 2.7% of patients reported having a family member with a PCD (defined as MGUS, MM, or AL…
Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis #mmsm #amyloidosis #mgus @myelomaMD @VincentRK https://t.co/4kct1cEK8B
-
-
Mashup Score: 0Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms - Leukemia - 3 year(s) ago
Multiple myeloma (MM) is a biologically heterogeneous malignancy, however, the mechanisms underlying this complexity are incompletely understood. We report an analysis of the whole-genome sequencing of 765 MM patients from CoMMpass. By employing promoter capture Hi-C in naĂŻve B-cells, we identify cis-regulatory elements (CREs) that represent a highly enriched subset of the non-coding genome in…
Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
Whole-genome sequencing [WGS] of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms [Apr 9, 2018] Phuc H. Hoang et al. @LeukemiaJnl https://t.co/NFLnBKDo3Y #mmsm #cagenome
-
-
Mashup Score: 5The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML - Leukemia - 3 year(s) ago
FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. We have previously described FLT3-ITD-dependent phosphorylation of CSF2RB, the common receptor beta chain of IL-3, IL-5, and GM-CSF, and therefore…
Source: LeukemiaCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML Read for free: https://t.co/qnMK3MsisG #Oncogenesis #Translationalresearch #Acutemyeloidleukaemia https://t.co/0CS20g2I1g
-
-
Mashup Score: 0Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice - Leukemia - 3 year(s) ago
Recurrent loss-of-function mutations of BCL6 co-repressor (BCOR) gene are found in about 4% of AML patients with normal karyotype and are associated with DNMT3a mutations and poor prognosis. Therefore, new anti-leukemia treatments and mouse models are needed for this combinatorial AML genotype. For this purpose, we first generated a Bcorâ/â knockout mouse model characterized by impaired erythroid…
Source: LeukemiaCategories: Hem/Oncs, Latest HeadlinesTweet-
However, data exists that Bcor deficiency perturbs erythro-megakaryopoiesis>> erythroid lineage bias. in cooperation w/Dnmt3a loss>>can trigger  acute erythroid leukemia in mice https://t.co/NqZKX3GVso
-
-
Mashup Score: 1
Adolescent and young adult (AYA) patients 16â30 years old with high-risk acute lymphoblastic leukemia (HR-ALL) have inferior outcomes compared to younger HR-ALL patients. AALL0232 was a Phase 3 randomized Childrenâs Oncology Group trial for newly diagnosed HR B-ALL (1â30 years). Between 2004 and 2011, 3154 patients enrolled with 3040 eligible and evaluable for induction. AYA patients comprised…
Source: LeukemiaCategories: Hematologists1, Latest HeadlinesTweet-
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Childrenâs Oncology Group Study AALL0232 | Leukemia https://t.co/dz0euC6fO9
-
8/ Zanwar et al. ORR 45% mPFS 4m and mOS 1 year slightly longer but still dismal. Outcomes of pentaref almost identical. https://t.co/mqeEg8wooz